Nachrichten zur Moderna Inc. Aktie

MNRA STOCK NEWS: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Moderna, Inc. Class Action

Robbins LLP is Investigating Allegations that Moderna, Inc. (MRNA) Misled Investors Regarding the Efficacy of its RSV Vaccine…

Healthy Returns: The race to develop combination shots targeting Covid, flu is heating up

Pfizer faced a setback with its combo Covid-flu shot, which could allow Moderna and others to gain ground. Meanwhile,…

Blitz-Update: Dow kaum bewegt, Walmart, Palo Alto, Amer Sports stark, Boeing, Moderna, Tesla schwach

Nach dem starken Wochenauftakt am Montag tun sich die US-Aktienmärkte am Dienstag schwer. Alle wichtigen Indizes notieren leicht im Minus.…

Blitz-Update: Dow kaum bewegt, Walmart, Palo Alto, Amer Sports stark, Boeing, Moderna, Tesla schwach

Nach dem starken Wochenauftakt am Montag tun sich die US-Aktienmärkte am Dienstag schwer. Alle wichtigen Indizes notieren leicht im Minus.…

Schluss Wall Street: Dow & Co geben Gas, Intel, AMD, Nvidia, Moderna, BioNTech, Viking extrem stark

Die US-Märkte haben nach einem zögerlichen Start am Montag am Ende doch noch deutlich zulegen können. Der US-Leitindex Dow Jones…

Schluss Wall Street: Dow & Co geben Gas, Intel, AMD, Nvidia, Moderna, BioNTech, Viking extrem stark

Die US-Märkte haben nach einem zögerlichen Start am Montag am Ende doch noch deutlich zulegen können. Der US-Leitindex Dow Jones…

BioNTech: Deutliche Zugewinne zum Wochenstart - Aktienanalyse

Kulmbach (www.aktiencheck.de) - BioNTech-Aktienanalyse von "Der Aktionär": Marion Schlegel vom Anlegermagazin "Der Aktionär" nimmt die Aktie von BioNTech SE (ISIN: US09075V1026,…

BioNTech und Moderna mit kräftigem Kursplus – die Hintergründe

Die Aktie von BioNTech und Moderna können zum Wochenstart deutliche Zugewinne verzeichnen. Beide Werte unterstützt die jüngste Entwicklung zu Corona…

BioNTech und Moderna mit kräftigem Kursplus – die Hintergründe

Die Aktie von BioNTech und Moderna können zum Wochenstart deutliche Zugewinne verzeichnen. Beide Werte unterstützt die jüngste Entwicklung zu Corona…

Pfizer and BioNTechs Combo Shot Missed the Mark. Is It Time to Sell? @themotleyfool #stocks $PFE $MRNA $BNTX

A clinical-trial failure for Pfizer and BioNTech means Moderna is leading the race to develop a combo shot for the…

Pfizer and BioNTechs Combo Shot Missed the Mark. Is It Time to Sell?

A clinical-trial failure for Pfizer and BioNTech means Moderna is leading the race to develop a combo shot for the…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna and Sprinklr and Encourages Investors to Contact the Firm

NEW YORK, Aug. 18, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

MRNA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Moderna, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

NEW YORK, Aug. 18, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally…

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRNA

NEW YORK, Aug. 16, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

Moderna: Kurszielsenkung

New York (www.aktiencheck.de) - Rating-Update: J.P. Morgan Securities stuft die Aktie von Moderna Inc. (ISIN: US60770K1079, WKN: A2N9D9, Ticker-Symbol: 0QF, NASDAQ-Symbol:…

MODERNA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Moderna, Inc. and Encourages Investors to Contact the Firm

NEW YORK, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights…

Stockholder Alert: Robbins LLP Informs Moderna, Inc. Stockholders that a Shareholder Filed a Class Action Against MRNA

Robbins LLP is Investigating Allegations that Moderna, Inc. (MRNA) Misled Investors Regarding the Efficacy of its RSV Vaccine…

Updated COVID Vaccines Are Coming: Effectiveness, Who’s Eligible And More

Pfizer and Moderna’s updated vaccines will be available for people six months and older, while Novavax’s vaccine will be aimed…

Moderna: Kurszielreduzierung

Minneapolis (www.aktiencheck.de) - Rating-Update: Edward Tenthoff, Analyst von Piper Sandler, bewertet die Aktie von Moderna Inc. (ISIN: US60770K1079, WKN: A2N9D9, Ticker-Symbol:…

Moderna: Verlustserie geht weiter - Aktienanalyse

Kulmbach (www.aktiencheck.de) - Moderna-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie von…

Apple, Nvidia, Intel, Coinbase and Moderna fall premarket By Investing.com

Apple, Nvidia, Intel, Coinbase and Moderna fall premarket…

Moderna plunges on downgrade amid vaccine headwinds By Investing.com

Moderna plunges on downgrade amid vaccine headwinds…

Moderna: Kursziel um 35 USD angepasst

Toronto (www.aktiencheck.de) - Rating-Update: Die Analysten vom Investmenthaus RBC Capital Markets stufen die Aktie von Moderna Inc. (ISIN: US60770K1079, WKN: A2N9D9,…

Moderna: Kursziel gekürzt

Zürich (www.aktiencheck.de) - Rating-Update: Die Analysten der UBS stufen die Aktie von Moderna Inc. (ISIN: US60770K1079, WKN: A2N9D9, Ticker-Symbol: 0QF, NASDAQ-Symbol:…

Moderna-Aktie unter Druck - BofA senkt Kursziel - Aktienanalyse

Charlotte (www.aktiencheck.de) - Moderna-Aktienanalyse von BofA Securities: Die Analysten von BofA Securities stufen die Aktie von Moderna Inc. (ISIN: US60770K1079, WKN:…

July jobs report, Amazon and Intel drag on stocks: Yahoo Finance

Wall Street is reacting to the July jobs report. Economists had expected the economy to have added 175,000 jobs and…

Whos to blame as Modernas stock falls amid slashed guidance?

…

Moderna (MRNA) Q2 2024 Earnings Call Transcript

MRNA earnings call for the period ending June 30, 2024.…

Moderna (MRNA) Q2 2024 Earnings Call Transcript

MRNA earnings call for the period ending June 30, 2024.…

Meta Platforms, Shake Shack rise; Moderna, Goodyear fall, Thursday, 8/1/2024

Stocks that traded heavily or had substantial price changes on Thursday: Meta Platforms, Shake Shack rise; Moderna, Goodyear fall…

Moderna shares drive on slashed 2024 sales forecast

Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares plummeted almost 20% after the vaccine maker slashed its full-year sales forecast for respiratory vaccines…

Moderna shares dive on slashed 2024 sales forecast

Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares plummeted almost 20% after the vaccine maker slashed its full-year sales forecast for respiratory vaccines…

Moderna: Aktie bricht ein - Aktienanalyse

Kulmbach (www.aktiencheck.de) - Moderna-Aktienanalyse von "Der Aktionär": Andreas Deutsch vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie von…

Moderna vs. BioNTech: Kurssturz bei Moderna beeinflusst Konkurrenten

Die jüngsten Quartalszahlen von Moderna haben zu einem signifikanten Kurssturz der Aktie geführt, nachdem das Unternehmen einen Verlust von 3,33…

Meta Platforms, Ferrari, ConocoPhillips rise premarket; Arm, Moderna fall By Investing.com

Meta Platforms, Ferrari, ConocoPhillips rise premarket; Arm, Moderna fall…

Moderna cuts guidance on low EU sales, competitive vaccine environment in the U.S. By Investing.com

Moderna cuts guidance on low EU sales, competitive vaccine environment in the U.S.…

Moderna stock falls more than 10% as it slashes guidance on low EU sales, tough U.S. vaccine market

Moderna now expects 2024 product revenue to come in between $3 billion and $3.5 billion, down from a previous guidance…

Moderna’s stock slides 12% after it lowers full year sales guidance

Moderna Inc.’s stock tumbled 12% premarket Thursday, after the biotech cut its sales guidance for 2024, offsetting a narrower-than-expected second-quarter...…

Moderna beats estimates but slashes guidance on low EU sales, competitive U.S. vaccine market

Moderna now expects 2024 product revenue to come in between $3 billion and $3.5 billion, down from a previous guidance…

Moderna reins in 2024 sales forecast, expects very low EU vaccine revenue By Reuters

Moderna reins in 2024 sales forecast, expects very low EU vaccine revenue…

Moderna (MRNA) Q2 Earnings Beat, Stock Down on Guidance Slash

Moderna (MRNA) beats expectations for earnings and sales. Management cuts sales guidance by $0.5-$1.0 billion on concerns about competition for…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA

NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

Moderna (MRNA) Stock Before Q2 Earnings: To Buy or Not to Buy?

Investors will likely focus on updates on Modernas (MRNA) pipeline, especially its late-stage pipeline candidates when it reports second-quarter earnings.…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA

NEW YORK, July 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

Moderna (MRNA) Stock Rises 22% YTD: Time to Buy the Stock?

Shares of Moderna (MRNA) continue to soar thanks to the encouraging development of its non-COVID pipeline. The companys potential product…

Is Moderna Stock a Buy?

The biotech is proving that its not a pandemic stock.…

Flagship Pioneering Raises $3.6B for New Wave of Health, AI Innovation

Biotech investor Flagship Pioneering has raised $3.6 billion dollars for ventures in health, sustainability and AI. With $14 billion dollars…

Microsoft, Apple Drop OpenAI Board Plans | Bloomberg The Pulse 07/10/24

Microsoft and Apple dropped plans to take board roles at OpenAI in a surprise decision that underscores growing regulatory scrutiny of Big Tech’s…

Biotech investor behind Moderna raises $3.6bn for new ventures

Incubator Flagship Pioneering plans to finance and launch array of companies using AI for pharmaceutical development…

Play Likely Earnings Beat With 5 Top-Ranked Stocks

Top-ranked stocks Chewy (CHWY), Wingstop (WING), Moderna (MRNA), Tenet Healthcare (THC) and Kinross Gold (KGC) are likely to beat on…